人福医药：公司控股股东招商生科质押约9793万股

Group 1 - Company announcement: Renfu Pharmaceutical (SH 600079) disclosed that its controlling shareholder,招商生科, pledged approximately 40.43 million unrestricted shares and 57.5 million restricted shares, totaling about 97.93 million shares [1] - Revenue composition for Renfu Pharmaceutical for the year 2024 is as follows: pharmaceuticals account for 56.01%, pharmaceutical wholesale and related businesses account for 43.8%, and other businesses account for 0.19% [1] - Current market capitalization of Renfu Pharmaceutical is 33.4 billion yuan [1]